news

television, radio, and podcasts

Feb 2025: Weight loss drugs may become harder to get. What does that mean for patients?. WBUR [NPR station].

Sept 2024: Recap of Novo Nordisk Hearing. BBC World Service.

Sept 2024: What the Maker of Ozempic Doesn’t Want You to Know: It’s Bankrupting America. More Perfect Union.

June 2024: Sanders calls on Ozempic maker to lower price of drug. CNN interview with Senator Bernie Sanders.

Apr 2024: How one state is trying to make weight loss drugs cheaper. NBC.

Apr 2024: American people are ‘sick and tired’ of being ‘ripped off by drug companies’. MSNBC interview with Senator Bernie Sanders.

Mar 2024: New study details costs of making diabetes drugs. CNBC “Fast Money”.

Sept 2023: Hearing: Legislative Proposals to Prevent and Respond to Generic Drug Shortages. C-SPAN.

Sept 2022: California plans to make its own insulin and sell it super-cheap. Really. An Arm and a Leg.

Jan 2022: Report: La vigile attesa. RAI (Radiotelevisione italiana).

Oct 2021: KNX In Depth (live LA current affairs radio show). KNX Radio

print and online media

Apr 17: Patients of rare disease welcome prospect of dramatic slash in price of drug. The Times of India.

Apr 16: Pharma companies expected to absorb any tariff hit in short term. Reuters.

Mar 26: Indian company can now make Spinal Muscular Atrophy drug, High Court cites public interest. Indian Express.

Mar 24: Delhi HC rejects Roche’s plea to block Natco Pharma on Risdiplam patent. Economic Times.

Mar 18: Balancing Health Rights and Resource Constraints: The Dilemma of Rare Disease Treatment in India. Geneva Health Files.

Mar 13: Trump’s Tariffs Threaten US Drug Prices. Observer Voice.

Mar 12: US tariffs on India will be a bitter pill to swallow. BBC.

Feb 28: High cost patented drugs a crippling blow to those with rare diseases. The Times of India.

Feb 12: For Many, Weight-Loss Drugs Are Pricey. Expanding Access Is Hard. Undark Magazine.

Feb 2: Yale experts weigh in on U.S. WHO exit. Yale News.

Jan 25: People with spinal muscular atrophy demand urgent action from the Centre to reduce medicine costs. The Hindu.

Jan 20: A Rare Invocation for a Rare Disease?: Government Urged to Invoke Section 100, Patents Act for Rare Disease Medicine. SpicyIP

Jan 8: Experts seek affordable access to medicines for treating Spinal Muscular Atrophy. The Hindu.

Nov 10: How many patients must die to pay the debt to drug innovation: Interview with Dr Melissa Barber. Times of India. Print version

Nov 6: Patient health body opposes move to bar generic SMA drug. Hindustan Times.

Nov 6: Swiss firm Roche bid to prevent India’s Natco Pharma from introducing cheap spinal drug. The Telegraph.

Nov 6: Patents and high price barriers: patients with rare diseases face woes to access medicines from MNCs. The Economic Times.

Nov 5: How a Rs 72 lakh drug for a rare genetic disease could cost just Rs 3,000. India Today.

Oct 28: Rs 72 lakh/year rare-disease drug can be made for Rs 3,000/year, High Court told. Times of India.

Oct 28: (Could a Rs 72 lakh drug cost just Rs 3,000? A 24-year-old’s courtroom revelation.)[https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/could-a-rs-72-lakh-drug-cost-just-rs-3000-a-24-year-olds-courtroom-revelation/articleshow/114679955.cms]. Economic Times.

Oct 7: Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries. New York Times.

Sept 24: Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers. USA Today.

Sept 24: Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad. Washington Post.

Sept 23: Analysts say market forces will lower cost of obesity drugs. Roll Call.

July 5: Health—if you can afford it. Yale Alumni Magazine.

July 2: President Biden: Novo Nordisk, Eli Lilly must stop ripping off Americans with high drug prices. USA Today.

June 26: Wegovy And Ozempic Are Overpriced By 400-500% — Here’s A Quick Solution. Forbes.

May 2: What is behind the insulin shortage in the US?. Al Jazeera.

Apr 29: MSF publishes clinical trial cost, challenges pharma to do the same. The Times of India.

Apr 25: Cost of developing new drugs may be far lower than industry claims, trial reveals. The Guardian.

Apr 24: This Is What a Miracle Drug Looks Like, and It Costs Only $5 to Make. The New York Times.

Apr 24: Diabetes Medication Can Be Manufactured at Lower Cost, New Study Says. Yale News.

Apr 16: «Fett-weg»-Spritzen könnten statt 150 nur 20 Franken kosten. Infosperber.

Apr 6: El “estilo de vida europeo” que asfixia la salud pública de África. El Pais.

Apr 2: MSF denuncia los “desorbitados” precios de los nuevos medicamentos para la diabetes. La Razón (Spain).

Apr 1: MSF study reveals global double standard in diabetes care. Development Aid.

Mar 29: Research flags excessive ‘profiteering’ on diabetes drugs by sections of pharmaceutical industry. The Telegraph India.

Mar 29: Weight-loss drugs cost $1,000 a month but less than $25 to make. Why do we pay so much?. USA Today.

Mar 29: Ozempic costs just $5 to make, a study said. The backlash was swift.. Quartz.

Mar 29: GLP-1 generics would be dramatically cheaper than U.S. price of Ozempic, study shows, but still profitable.. Stat News.

Mar 29: Nyt studie: Populær medicin koster alt, alt for meget. BT (Denmark).

Mar 28: Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed. The Guardian.

Mar 28: Sanders presses Novo Nordisk over Ozempic, Wegovy prices. The Washington Post.

Mar 28: MSF’s costing study says newer diabetes drugs and insulin pens priced beyond patient reach. The Hindu.

Mar 28: Bernie Sanders wants to make Ozempic cheaper. Business Insider.

Mar 28: Bernie Sanders implores Novo to cut list prices of Ozempic, Wegovy. Endpoints News.

Mar 28: Costly Ozempic jab, which costs up to $1,300, can be made for just $5, study claims. New York Post.

Mar 28: High prices on GLP-1 meds, insulin pens raise barriers to access in lower-income countries: MSF. Fierce Pharma.

Mar 28: Amerikanen betalen er bijna 1.000 euro per maand voor, maar afvalmiddel Ozempic kan “voor nog geen 5 dollar” gemaakt worden. Het Laatste Nieuws (Belgium).

Mar 28: Ozempic makers could be raking in 40,000% profit — study says diabetes drug can be made for $1/month. The Print.

Mar 28: Medicamentos modernos para a diabetes são vendidos 400 vezes mais caros do que o necessário, denuncia estudo. Sapo (Portugal).

Mar 27: ‘Huge markup on prices of new diabetes medicines and insulin pens’. The Times of India.

Mar 27: Sanders calls for Novo Nordisk to slash Ozempic, Wegovy prices. Office of Bernie Sanders.

Mar 27: Novo Nordisk’s $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests. CNBC.

Mar 27: Weight-loss drug ‘could be profitably made for as little as €4.40 a month’. Irish Examiner.

Mar 27: Sanders calls for Novo Nordisk to slash Ozempic, Wegovy prices. The Hill.

Mar 27: Ozempic, Novo’s $1,000 Diabetes Shot, Can Be Made for Under $5 a Month. Bloomberg.

Mar 27: Ozempic, the $1,000 diabetes drug, can be made for less than $5 a month: study. Ottawa Citizen.

Nov 29: Why it’s time to spotlight the harms of supply shortages. Association of Health Care Journalists.

Sept 15: Health subcommittee members at odds over drafted drug shortage legislation. Fierce Healthcare.

Sept 14: No ‘Silver Bullet’ for Generic Drug Shortage, House Members Told. Medpage Today.

Sept 14: Partisan divide on drug shortages unresolved after hearing. Roll Call News.

May 2: Introducing the 2023 ASHEcon Award Winners. American Society of Health Economists.

July 22: Lucro das maiores farmacêuticas cresce 41% na pandemia. Poder360.

July 22: Farmacêuticas podiam cobrar menos, diz pesquisadora de Harvard. Poder360.

July 12: How Many Variants And Deaths Are We Willing To Accept, Before We Protect The Whole World?. Forbes.

June 17: W.T.O. countries agree to a limited relaxing of patent protections on coronavirus vaccines. New York Times.

May 25: Behind Pfizer’s new not-for-profit deal on patented vaccines and drugs. Devex.

Apr 4: African clinical trial denied access to key COVID drug Paxlovid. Nature.

Feb 28: Paxlovid e Molnupiravir, pillola anti-Covid: il ricatto delle case farmaceutiche ai sistemi sanitari. Corriere della Sera.

Oct 4: Merck’s Covid-19 pill may be a game-changer, but questions are already being raised about cost. STAT.

Oct 19: WHO-led programme aims to buy antiviral COVID-19 pills for $10 -document. Reuters.

Oct 17: Will New Covid Treatments Be as Elusive for Poor Countries as Vaccines?. New York Times.

Oct 7: Merck slammed for 4,000% markup of taxpayer-funded COVID-19 drug. Salon.

Oct 6: Buyers clamor for Merck’s COVID-19 antiviral molnupiravir, but pricing is already controversial. Fierce Pharma.

Oct 6: Covid pill makers accused of selling drug to US at 40 times what it costs to make despite govt funding. Independent.

Oct 5: Merck Sells Federally Financed Covid Pill to U.S. for 40 Times What It Costs to Make. The Intercept.

Oct 4: Indian Generic Companies Are Ready to Make Merck’s COVID-19 Antiviral Pill. Fortune India.

Oct 4: Indian Generic Companies Are Ready to Make Merck’s COVID-19 Antiviral Pill. Health Policy Watch.

Sept 29: La insulina podría ser más barata sin que las farmacéuticas pierdan ganancias, según estudio. El Espectador.

Aug 16: States are trying to cap the price of insulin. Pharmaceutical companies are pushing back. NBC.

Nov 15: Elizabeth Warren’s First Term Plan for Reducing Health Care Costs in America and Transitioning to Medicare for All. Medium.

Oct 8: Why would the government make its own drugs?. New Statesman.

June 25: Why Insulin Defies The Normal Rules Of Economics And Keeps Getting More Expensive. WBUR.

Sept 25: Insulin prices could be much lower and drug makers would still make healthy profits. STAT.

May 31: The drug rebellion fighting big pharma to save the NHS millions. New Scientist.

May 16: EU starts investigation of Aspen’s cancer drug pricing. PmLiVE.

Jan 30: Price hikes for some generic cancer drugs in the UK have skyrocketed. STAT.

Jan 29: Cancer drugs price rise ‘costing NHS millions’. BBC.

Jan 28: Drugs firms are accused of putting cancer patients at risk over price hikes. The Guardian.